Drug intelligence / Profile preview

ah-003

Development stage: Preclinical
Lead developer: AnHorn Medicines
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

AH-003 is a proteolysis-targeting chimera (PROTAC) drug candidate developed as an androgen receptor (AR) antagonist. It is being investigated for the treatment of neoplasms and urogenital diseases, with its primary active indication being prostatic cancer. The drug was initially developed by AnHorn Medicines Co., Ltd., and its highest global R&D status is preclinical[1][3].

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on ah-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ah-003.

Explore the full profile